Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 4 |
Neoplasms | 4 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Monoclonal antibody | 1 |
Top 5 Target | Count |
---|---|
JAK2(Tyrosine-protein kinase JAK2) | 4 |
CXCL4(platelet factor 4) | 1 |
Target |
Mechanism JAK2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism JAK2 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism JAK2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2025 |
Sponsor / Collaborator ![]() [+1] |
Start Date31 Jul 2025 |
Sponsor / Collaborator |
Start Date28 Jul 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
JAK315 ( JAK2 ) | Myeloproliferative Disorders More | Preclinical |
JAK190 ( JAK2 ) | Myeloproliferative Disorders More | Preclinical |
NVP-BBT594 ( JAK2 ) | Myeloproliferative Disorders More | Preclinical |
NVP-CHZ868 ( JAK2 ) | Myeloproliferative Disorders More | Preclinical |
WO2023178390 ( CXCL4 )Patent Mining | Rare Diseases More | Discovery |